Daewon Pharmaceutical Reports First-Half Sales of 310.9 Billion Won, Up 3.1% Year-on-Year

Growth in Chronic Disease Pharmaceuticals and Health Functional Foods
Health Functional Food Sales Reach 20.7 Billion Won
Operating Profit Down 45.3%... Net Profit Up 308%

Daewon Pharmaceutical announced on August 7, 2026, that, on a consolidated basis for the first half of the year, it recorded sales of 310.9 billion won, operating profit of 4.4 billion won, and net profit of 5.7 billion won.

Daewon Pharmaceutical company logo image. Daewon Pharmaceutical

Sales increased by 3.1% compared to the same period last year. While sales of flagship products such as Pelubi and Kodaewon declined due to drug price reductions and the absence of a respiratory disease outbreak, expansion in prescriptions for chronic disease product lines such as the Idalbi family, as well as strong sales of health functional foods, drove overall growth.

Sales from the health functional foods segment amounted to 20.7 billion won, marking a 639% increase year-on-year. Increased sales of the sleep health food ‘Kkuljamsot’ and hair and skin health product ‘Mobalkollagen3X’ contributed to this growth.

Operating profit was 4.4 billion won, down 45.3%. This was due to an 8.8% year-on-year increase in selling and administrative expenses, resulting from higher R&D spending on new drugs and increased marketing costs related to the launch of new health functional food products.

By contrast, net profit reached 5.7 billion won, a 308.0% increase compared to 1.4 billion won during the same period last year, thanks to improvements in non-operating income such as gains from the disposal of investment assets.

A representative from Daewon Pharmaceutical stated, “In the second half of the year, we will continue diversifying our portfolio in the chronic disease and health functional food sectors, while also pursuing improved profitability and sustainable growth through cost efficiencies.”

This content was produced with the assistance of AI translation services.